Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.36 |
| ▸ | FPR2 | P25090 | 5/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2830839 | 0.93 | FOLH1 (0.41) | FOLH1TDP1MEN1KMT2A | |
| SCHEMBL17690558 | 0.93 | FOLH1 (0.35) | FOLH1FPR2TDP1 | |
| SCHEMBL2831636 | 0.93 | FOLH1 (0.35) | FOLH1FPR2TDP1 | |
| SCHEMBL13237046 | 0.91 | FOLH1 (0.36) | FOLH1 | |
| SCHEMBL2834575 | 0.90 | FOLH1 (0.39) | FOLH1FPR2TDP1MEN1KMT2A | |
| SCHEMBL2834585 | 0.90 | FOLH1 (0.39) | FOLH1FPR2TDP1MEN1KMT2A | |
| SCHEMBL15501039 | 0.89 | FPR2 (0.32) | FOLH1FPR2TDP1MEN1KMT2A | |
| SCHEMBL13287689 | 0.89 | FPR2 (0.34) | FPR2TDP1 | |
| SCHEMBL15834896 | 0.86 | TDP1 (0.37) | FPR2TDP1MEN1KMT2A | |
| SCHEMBL1740688 | 0.85 | TDP1 (0.37) | FPR2TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9433594-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433594-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| EP-2389361-B1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARM INC (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2389361-B1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARM INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20160222036-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160222036-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| EP-2706057-B1 | Bis(imidazolyl)compounds and radionuclide complexes | MOLECULAR INSIGHT PHARM INC (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2706057-B1 | Bis(imidazolyl)compounds and radionuclide complexes | MOLECULAR INSIGHT PHARM INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8962799-B2 | Technetium—and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140341805-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8562945-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8211401-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211401-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211401-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | PSMA1, PSMA5, PSMA3 | FOLH1 4/4885FPR2 4575/4885TDP1 3443/4885 |
| US-20140341805-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | RAB35, SLC39A14, SLC39A3 | FOLH1 283/4885FPR2 1849/4885TDP1 2624/4885 |
| US-20160222036-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | RAB35, SLC39A14, SLC39A3 | FOLH1 283/4885FPR2 1849/4885TDP1 2624/4885 |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | SSTR5, SSTR3, SSTR4 | FOLH1 216/4885FPR2 1076/4885TDP1 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.